Bladder Cancer: Risk Factors, Emerging Treatment Strategies and Challenges

Samantha Haggerty (Editor)

Series: Cancer Etiology, Diagnosis and Treatments
BISAC: MED062000

Clear

$192.00

Volume 10

Issue 1

Volume 2

Volume 3

Special issue: Resilience in breaking the cycle of children’s environmental health disparities
Edited by I Leslie Rubin, Robert J Geller, Abby Mutic, Benjamin A Gitterman, Nathan Mutic, Wayne Garfinkel, Claire D Coles, Kurt Martinuzzi, and Joav Merrick

eBook

Digitally watermarked, DRM-free.
Immediate eBook download after purchase.

Product price
Additional options total:
Order total:

Quantity:

Details

Bladder cancer is the fifth most common form of cancer worldwide and is mainly prevalent in developed countries. It is thought to arise through two distinct pathways: the noninvasive and the invasive. The noninvasive pathway gives rise to a superficial papillary carcinoma that is characterized by activating mutations in oncogenes such as H-ras, FGFR3 and PI3K.

This pathway is rarely lethal as superficial papillary carcinomas can be readily removed through transurethral resection. However, 15% of noninvasive urothelial tumors can transform into invasive carcinomas and have high recurrence (80% of the cases) that requires intensive surveillance and repetitive treatment. This book discusses the risk factors of bladder cancer, as well as the emerging treatment strategies and challenges. (Imprint: Nova Biomedical )

Preface

Chapter 1 - Cancer Stem Cell (CSC) in Bladder Malignancy (pp. 1-16)
Jianmin Zhang, Maxime Blijlevens and Nuo Yang (Department of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, NY, USA, and others)

Chapter 2 - The Five Senses in Bladder Cancer Diagnostics (pp. 17-44)
Caterina Gulia, Giacinto Marrocco, Santiago Vallasciani and Roberto Piergentili (Dipartimento di Scienze Ginecologico-Ostetriche e Scienze Urologiche, Policlinico Umberto I, Sapienza - Università di Roma, Italy, and others)

Chapter 3 - Bladder Cancer in Pediatric Patients (pp. 45-70)
Santiago Vallasciani, Giacinto Marrocco, Caterina Gulia, Andrea Zangari and Roberto Piergentili (UOSD di Urologia Pediatrica, Policlinico Maggiore, Milano, Italy, and others)

Chapter 4 - Multi-Tasking Chemoinformatic Model for the Efficient Discovery of Potent and Safer Anti-Bladder Cancer Agents (pp. 71-94)
Alejandro Speck-Planche and M. N. D. S. Cordeiro (REQUIMTE/Department of Chemistry and Biochemistry, University of Porto, Porto, Portugal)

Chapter 5 - Long Non Coding Mitochondrial RNAs As Potential Targets for Diagnosis and Therapy of Bladder Cancer (pp. 95-116)
Jaime Villegas, Alexis Rivas, Rodolfo Ávila, Vincenzo Borgna, Lorena Lobos-Gonzales Verónica Burzio, Constanza López, Reynaldo Gomez, Eduardo Landerer, Laura Velarde and L. O. Burzio (Andes Biotechnologies S.A., Fundación Ciencia & Vida, Chile, and others)

Chapter 6 - Histological Variants of Urothelial Carcinoma: Diagnostic, Prognostic and Therapeutic Implications (pp. 117-144)
Hyung Suk Kim and Ja Hyeon Ku (Department of Urology, Seoul National University College of Medicine)

Chapter 7 - Novel Therapeutic Modalities in Patients with Advanced or Metastatic Urothelial Carcinoma (pp. 145-160)
Kazumasa Matsumoto, Masaomi Ikeda, Takahiro Hirayama, Tetsuo Fujita and Masatsugu Iwamura (Department of Urology, Kitasato University School of Medicine)

Index

You have not viewed any product yet.